Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05256069 · ClinicalTrials.gov registry record · Early Phase 1

Sex-related Differences in Sympathetic Vascular Transduction in the Setting of Hypoxemia

A Early Phase 1 study, sponsored by University of Missouri-Columbia.

Completed
Registry status
Early Phase 1
Development phase
31
Enrollment target

NCT05256069 is a Early Phase 1 study that has completed, run by University of Missouri-Columbia. The registered enrollment target is 31 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05256069, a Early Phase 1 study, has completed, sponsored by University of Missouri-Columbia.

COMPLETED
Registry status
Early Phase 1
Development phase
31 participants
Enrollment target

Study Summary

The purpose of this project is to identify sex-related differences in the effect of hypoxia on sympathetic vascular transduction.

Interventions

  • DRUG Placebo
  • DRUG Propranolol Pill

Trial Details

FieldValue
Enrollment Target 31 participants
Start Date 2023-04-26
Est. Completion 2025-07-31
Phase Early Phase 1

Sponsor

University of Missouri-Columbia

291 total trials

What the Registry Record Tells You About NCT05256069

The ClinicalTrials.gov registry entry for NCT05256069 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Missouri-Columbia, which has 291 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT05256069 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT05256069 about?

NCT05256069 is a clinical study titled "Sex-related Differences in Sympathetic Vascular Transduction in the Setting of Hypoxemia". The purpose of this project is to identify sex-related differences in the effect of hypoxia on sympathetic vascular transduction.

What is the current status of trial NCT05256069?

This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 31 participants. The study started on 2023-04-26. Estimated completion is 2025-07-31.

What interventions are being tested in trial NCT05256069?

The interventions under investigation include: Placebo (DRUG), Propranolol Pill (DRUG).

Who is sponsoring clinical trial NCT05256069?

This trial is sponsored by University of Missouri-Columbia, which has 291 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.